Vision

CMaT's vision is to transform the manufacture of cell-based therapeutics into a large-scale, lower-cost, reproducible, and high-quality Quality-by-Design (QbD)-driven engineered system for broad industry and clinical use. In the past six years, CMaT has become a globally-recognized visionary and strategic international resource and an exemplar for developing new knowledge, transformative technologies, a well-trained workforce, and for enabling standards for cell production and characterization processes. With re-alignment of thrusts and test-beds at the end of Y5, in Y6 and beyond CMaT has enabled convergent research in three synergistic research and technical innovation Thrusts which are integrated in three Engineered Systems (Test-Beds): 

Thrusts: 

• Data Science and AI in Cell-Manufacturing (Thrust 1) 

• Rapid, Relevant, Realtime Analytics (R3) of Process and Product (Thrust 2) 

• Process Development and Automation for QbD (Thrust 3) 

Test-Beds: 

• Mesenchymal Stromal Cells (MSCs) for immune modulation and musculoskeletal applications (Test-Bed 1) 

• T cell and NK cell-based immunotherapies applications (Test-Bed 2) 

• iPSC-derived cardiac, neural, and immune cells (Test-Bed 3).